23:52 , May 30, 2019 |  BC Innovations  |  Emerging Company Profile

Aro delivers bispecifics, siRNAs where others can’t

A year after its launch, Susan Dillon and Karyn O’Neil’s Aro has begun to reveal details about how the J&J spinout’s Centyrins could form small bispecifics and stable siRNA therapies to penetrate hard-to-reach cancers. Therapies...
00:35 , Feb 9, 2019 |  BC Extra  |  Company News

Emerging company roundup: HiberCell, Orexia, TamRx

At least five new biotechs launched this week to develop therapies spanning rare sleep disorders to cancer immunotherapy, while several other emerging companies are moving closer to key inflection points. Of the five newcos, HiberCell...
01:52 , Feb 8, 2019 |  BC Week In Review  |  Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Feb. 7 from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from...
23:45 , Feb 7, 2019 |  BC Extra  |  Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Thursday from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from Rutgers...
19:03 , Dec 14, 2018 |  BC Week In Review  |  Financial News

Janssen veterans raise $13M for Centyrin platform

Aro Biotherapeutics Co. (Philadelphia, Pa.) unveiled the lead programs from its Centyrin pipeline on Dec. 11, along with a $13 million seed round from Johnson & Johnson Innovation - JJDC Inc. and BioMotiv LLC (Cleveland,...
12:01 , Dec 11, 2018 |  BC Extra  |  Financial News

Janssen veterans raise $13M for Centyrin platform

Aro Biotherapeutics Co. (Philadelphia, Pa.) unveiled the lead programs from its Centyrin pipeline Tuesday, along with a $13 million seed round from Johnson & Johnson Innovation - JJDC Inc. and BioMotiv LLC (Cleveland, Ohio). Former...
17:24 , Aug 17, 2018 |  BC Week In Review  |  Company News

BioMotiv, Cure Network developing inhibitory interneuron small molecules

BioMotiv LLC (Cleveland, Ohio) partnered with Cure Network Dolby Acceleration Partners LLC (CNDAP) to develop small molecules that improve the function of inhibitor interneurons to treat neurological disorders, including Dravet syndrome, other epilepsies and Alzheimer’s...
20:15 , Feb 24, 2017 |  BioCentury  |  Finance

IPO for evergreen

A year after launching with an initial £52 million ($64.8 million), investment company Arix Bioscience plc (LSE:ARIX) has added £100 million ($125.2 million) to its coffers to support up to 15 direct investments across the...
21:04 , Jan 27, 2017 |  BC Week In Review  |  Financial News

Allinaire Therapeutics completes venture financing

On Jan. 26, pulmonary disease company Allinaire Therapeutics LLC (Cleveland, Ohio) raised $950,000 in seed financing from BioCrossroads’ Indiana Seed Fund II, BioMotiv and Indiana University’s Innovate Indiana Fund. Allinaire Therapeutics LLC , Cleveland, Ohio ...
07:00 , May 2, 2016 |  BC Week In Review  |  Company News

Charles River, BioMotiv deal

Charles River and BioMotiv partnered to advance candidates sourced from academia and NGOs using Charles River’s discovery and preclinical development services. Charles River will be the preferred drug discovery and preclinical development partner for BioMotiv’s...